{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:12:08Z","timestamp":1761156728106,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.tmrv.2019.06.005","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T10:03:40Z","timestamp":1565863420000},"page":"248-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies"],"prefix":"10.1016","volume":"33","author":[{"given":"Marshall A","family":"Mazepa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara A","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay S","family":"Raval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2019.06.005_bb0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJM199108083250611","article-title":"TTP\u2014desperation, empiricism, progress","volume":"325","author":"Moake","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0010","doi-asserted-by":"crossref","unstructured":"George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010;116:4060\u20139.","DOI":"10.1182\/blood-2010-07-271445"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0020","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor\u2013cleaving protease in acute thrombotic thrombocytopenic Purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0025","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor\u2013cleaving protease in thrombotic thrombocytopenic Purpura and the hemolytic\u2013uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0035","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor Multimers in chronic relapsing thrombotic thrombocytopenic Purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0040","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/trf.12794","article-title":"How we approach an acquired thrombotic thrombocytopenic purpura patient","volume":"54","author":"Raval","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jca.21302","article-title":"Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research","volume":"29","author":"Sarode","year":"2014","journal-title":"J Clin Apher"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0050","doi-asserted-by":"crossref","unstructured":"Mazepa MA, Raval JS, Brecher ME, Park YA. Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise. J Clin Apher 2017. doi:https:\/\/doi.org\/10.1002\/jca.21600.","DOI":"10.1002\/jca.21600"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0055","article-title":"How we treat thrombotic thrombocytopenic purpura: results of a Canadian TTP practice survey","author":"Patriquin","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jca.21261","article-title":"Medications and therapeutic apheresis procedures: are we doing our best?","volume":"28","author":"Ibrahim","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ajcp\/aqx056","article-title":"Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review","volume":"148","author":"Cheng","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0070","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk factors for autoimmune diseases development after thrombotic thrombocytopenic Purpura","volume":"94","author":"Roriz","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0085","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic Purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic Purpura\u2013hemolytic uremic syndrome: clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0100","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0105","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0115","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2018-99-113677","article-title":"Efficacy of adjuvant low dose rituximab and plasma exchange for acquired TTP with severe ADAMTS13 deficiency \u2014 results of the ART study","volume":"132","author":"Evan Sadler","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0120","first-page":"139","article-title":"Special issue abstracts from the American Society for Apheresis 39th annual meeting April 25-28, 2018, Chicago, Illinois","volume":"33","author":"Reddy","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0125","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjh.12696","article-title":"Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura","volume":"164","author":"Mazepa","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0130","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ejh.12206","article-title":"Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib","volume":"92","author":"van Balen","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0145","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/trf.13465","article-title":"Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib: RITUXIMAB-REFRACTORY TTP","volume":"56","author":"Patel","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215491","article-title":"Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura","volume":"2016","author":"Acedillo","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0155","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0160","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0165","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0170","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0180","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0185","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/trf.12440","article-title":"Treatment of refractory thrombotic thrombocytopenic purpura with N -acetylcysteine: a case report: treatment of TTP with N-acetylcysteine","volume":"54","author":"Li","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0190","article-title":"Administration of immunoglobulin G-degrading enzyme of streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission","author":"Stubbs","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0200","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ejh.12199","article-title":"Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia","volume":"91","author":"Barcellini","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0205","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor","volume":"6","author":"Bartunek","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0215","unstructured":"FDA approves Cablivi\u00ae (caplacizumab-yhdp), the first Nanobody\u00ae-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) - Feb 6, 2019 n.d. http:\/\/www.news.sanofi.us\/2019-02-06-FDA-approves-Cablivi-R-caplacizumab-yhdp-the-first-Nanobody-R-based-medicine-for-adults-with-acquired-thrombotic-thrombocytopenic-purpura-aTTP (accessed February 27, 2019)."},{"key":"10.1016\/j.tmrv.2019.06.005_bb0220","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","article-title":"Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic Purpura","volume":"35","author":"Tersteeg","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0225","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0230","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.113.006727","article-title":"Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy","volume":"129","author":"Tersteeg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0235","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1111\/jth.13859","article-title":"Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice","volume":"15","author":"Tersteeg","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0240","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","article-title":"N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura","volume":"129","author":"Tersteeg","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0245","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0250","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0260","first-page":"15","article-title":"Phase II, multiple-dose study of anti-FcRn antibody, Rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis","volume":"130","author":"Robak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0265","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0270","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Advances"},{"key":"10.1016\/j.tmrv.2019.06.005_bb0275","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/trf.14193","article-title":"Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial","volume":"57","author":"Uhl","year":"2017","journal-title":"Transfusion"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796318301214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796318301214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:53Z","timestamp":1760138333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796318301214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0887796318301214"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2019.06.005","relation":{},"ISSN":["0887-7963"],"issn-type":[{"type":"print","value":"0887-7963"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2019.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}